Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.52 |
| ▸ | THRA | P10827 | 18/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840313 | 1.00 | THRB (0.52) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840278 | 1.00 | THRB (0.52) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840350 | 0.92 | THRA (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840353 | 0.89 | THRB (0.54) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840372 | 0.89 | THRA (0.53) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840349 | 0.88 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840355 | 0.87 | THRA (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840334 | 0.85 | THRB (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840317 | 0.84 | THRB (0.56) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840371 | 0.83 | THRA (0.44) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112839655-A | Thyroid hormone receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 3737/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 3737/4885 |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, LIPC | THRB 19/4885THRA 25/4885CYP2C9 3141/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.